KRAS and cancer: To assess whether reducing PIP5K1A negatively impacts cellular proliferation of specifically KRAS-mutant human cancer cell lines, the above 43 derived cell lines were assayed twice in triplicate for changes in the number of metabolically active (viable) cells using the CellTiterGlo luminescence assay.